Jacobi Capital Management LLC Has $1.12 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Jacobi Capital Management LLC lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 13.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,941 shares of the medical instruments supplier’s stock after purchasing an additional 596 shares during the period. Jacobi Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $1,121,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BDX. US Bancorp DE boosted its stake in Becton, Dickinson and Company by 12.4% in the third quarter. US Bancorp DE now owns 83,383 shares of the medical instruments supplier’s stock valued at $20,104,000 after acquiring an additional 9,190 shares during the last quarter. Americana Partners LLC boosted its stake in Becton, Dickinson and Company by 3.5% in the third quarter. Americana Partners LLC now owns 1,468 shares of the medical instruments supplier’s stock valued at $354,000 after acquiring an additional 50 shares during the last quarter. Chicago Partners Investment Group LLC boosted its stake in Becton, Dickinson and Company by 24.4% in the third quarter. Chicago Partners Investment Group LLC now owns 1,628 shares of the medical instruments supplier’s stock valued at $392,000 after acquiring an additional 319 shares during the last quarter. Ceredex Value Advisors LLC bought a new position in Becton, Dickinson and Company in the third quarter valued at approximately $51,684,000. Finally, Fullcircle Wealth LLC boosted its stake in Becton, Dickinson and Company by 7.2% in the third quarter. Fullcircle Wealth LLC now owns 1,677 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 113 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Trading Up 0.6 %

BDX opened at $225.57 on Friday. The stock has a market capitalization of $64.77 billion, a P/E ratio of 37.47, a P/E/G ratio of 1.63 and a beta of 0.40. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99. The firm’s fifty day simple moving average is $233.08 and its 200 day simple moving average is $233.02. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.84%. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the sale, the executive vice president now directly owns 24,345 shares in the company, valued at approximately $5,380,488.45. The trade was a 15.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael David Garrison sold 2,838 shares of Becton, Dickinson and Company stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $223.33, for a total transaction of $633,810.54. Following the completion of the sale, the executive vice president now owns 6,141 shares in the company, valued at $1,371,469.53. The trade was a 31.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,544 shares of company stock valued at $2,370,309. 0.36% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Tuesday, February 25th. Finally, Barclays lifted their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and an average target price of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.